• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

    6/4/25 2:36:00 PM ET
    $BFLY
    $MDT
    $ORCL
    $RXRX
    Medical Electronics
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BFLY alert in real time by email

    Equity Insider News Commentary

    Issued on behalf of Avant Technologies Inc.

    VANCOUVER, BC, June 4, 2025 /PRNewswire/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc. (OTCQB:AVAI), Medtronic plc (NYSE:MDT), Butterfly Network, Inc. (NYSE:BFLY), Oracle Corporation (NYSE:ORCL), and Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX).

    Investor capital is pouring into AI-driven healthcare, with Pittsburgh-based Abridge AI Inc. pulling in $300 million at a $5.3 billion valuation. While several private players are making headlines, public markets are also heating up. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030 — a staggering 37% compound annual growth rate.

    Avant Technologies, Inc. (OTCQB:AVAI), in partnership with Ainnova Tech, is entering the final prototyping stage of a proprietary, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel.

    The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics.

    "The cost of a fundus camera has always been a barrier to entry in this market," said Vinicio Vargas, CEO at Ainnova and board member of AAC. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market."

    But hardware is only half the story. The new camera is being built to integrate seamlessly with Vision AI, Ainnova's diagnostic platform that uses retinal imaging, vital signs, and basic lab inputs to assess risk for a range of diseases. Already in use across clinical sites in Latin America, Vision AI currently supports risk scoring for diabetic retinopathy, glaucoma, age-related macular degeneration, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease.

    "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists," added Vargas. "Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach."

    The development comes at a critical time for Avant, which is in active talks to acquire Ainnova outright — a move that would consolidate leadership, simplify operations, and unify the companies under one roof ahead of a planned FDA pre-submission meeting scheduled for next month. The two companies already operate jointly through AAC, which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments.

    While Vision AI remains compatible with third-party imaging equipment, the decision to design proprietary hardware marks a strategic shift toward product exclusivity — giving Avant greater control over the end-to-end user experience and enhancing its defensibility in a competitive early diagnostics landscape.

    Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare.

    "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions."

    As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care.

    With hardware now entering the pipeline, software validated in clinical settings, and corporate consolidation on the table, Avant is no longer just building an AI model — it's building a diagnostic system.

    CONTINUED... Read this and more news for Avant Technologies at:

    https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

    Medtronic plc (NYSE:MDT) capped off its fiscal year with strong Q4 results, reporting $8.9 billion in revenue and double-digit earnings growth.

    "We had a strong close to our fiscal year, and I'm excited to see the progress we are making as our growth drivers continue to build momentum," said Geoff Martha, Chairman and CEO of Medtronic. "The underlying fundamentals of our business are strong, and they are getting stronger."

    The company highlighted progress across growth franchises, including the launch of BrainSense™ Adaptive Deep Brain Stimulation (aDBS) — its largest-ever commercial rollout of brain-computer interface technology, a milestone in precision neuromodulation. Additionally, Medtronic's AiBLE™ spine surgery ecosystem and connected insulin delivery platforms further signal its growing focus on AI-integrated healthcare solutions.

    Butterfly Network, Inc. (NYSE:BFLY) kicked off 2025 with strong execution, growing Q1 revenue 20% year-over-year to $21.2 million and narrowing its net loss to $14 million.

    "2025 is off to a great start. The Butterfly team hit the mark again, delivering right on target with a 20% growth quarter," said Joseph DeVivo, President, CEOah and Chairman of Butterfly Network. "We're very proud of how the Company continues to mature."

    The company advanced its Butterfly HomeCare pilot program and added two new AI developers to its Butterfly Garden, while existing partner DESKi secured FDA clearance for its AI-driven HeartFocus cardiac app. Its portable iQ3 ultrasound device continued gaining traction, featured on HBO Max's The Pitt and adopted by major U.S. med schools. With a strengthened balance sheet and increasing AI integration, Butterfly reiterated guidance for $96–100 million in 2025 revenue.

    Oracle Corporation (NYSE:ORCL), through its subsidiary Oracle Health, in partnership with Cleveland Clinic and G42, has announced a strategic collaboration to develop a global AI-powered healthcare delivery platform. The initiative will combine Oracle's cloud and AI infrastructure with Cleveland Clinic's clinical expertise and G42's advanced AI models to deliver scalable, secure, and affordable care.

    "Aging populations, rising costs, and the complexity of care demand a complete reinvention of how healthcare is provided," said Larry Ellison, Executive Chairman and CTO of Oracle. "Oracle's AI Data Platform and suite of clinical applications can help us understand disease and population health in ways that fuel scientific breakthroughs, reduce the cost of care delivery, and improve patient care. Together with Cleveland Clinic and G42, we will deliver the modern tools providers need to help people live longer, healthier lives."

    Designed to support precision medicine and real-time clinical intelligence, the platform aims to improve outcomes while reducing costs across the U.S., UAE, and beyond.

    Recursion Pharmaceuticcals, Inc. (NASDAQ:RXRX) announced early Phase 2 results from its TUPELO trial evaluating REC-4881 in patients with Familial Adenomatous Polyposis (FAP), a rare genetic disorder with no approved therapies.

    "For patients with FAP, who currently lack FDA-approved treatment options, Recursion's AI-powered Recursion OS platform identified a promising approach through MEK 1/2 inhibition," said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. "By analyzing cellular models of APC gene loss, we uncovered a potential first-in-disease treatment and are excited to share our preliminary findings."

    The AI-discovered MEK1/2 inhibitor reduced polyp burden by a median of 43% in just 13 weeks among evaluable patients, with 83% showing clinical response. The study also reported improvements in upper GI disease severity and a manageable safety profile consistent with known MEK inhibitors. REC-4881 was developed through Recursion's in-house AI platform, Recursion OS, which analyzed APC gene loss models to generate a novel treatment pathway.

    Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/  

    CONTACT:

    Equity Insider

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Video - https://www.youtube.com/watch?v=S6E7QQPfI_Y

    Logo - https://mma.prnewswire.com/media/2644233/5353895/Equity_Insider_Logo.jpg

    Equity Insider Logo (PRNewsfoto/Equity Insider)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-in-healthcare-just-crossed-a-tipping-point-investors-are-watching-these-names-302473611.html

    SOURCE Equity Insider

    Get the next $BFLY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BFLY
    $MDT
    $ORCL
    $RXRX

    CompanyDatePrice TargetRatingAnalyst
    Oracle Corporation
    $ORCL
    7/17/2025$300.00Sector Outperform
    Scotiabank
    Oracle Corporation
    $ORCL
    7/10/2025$270.00Neutral → Overweight
    Piper Sandler
    Recursion Pharmaceuticals Inc.
    $RXRX
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    Oracle Corporation
    $ORCL
    7/2/2025$235.00 → $245.00Outperform
    BMO Capital Markets
    Butterfly Network Inc.
    $BFLY
    7/1/2025$3.00Buy
    Craig Hallum
    Oracle Corporation
    $ORCL
    6/30/2025$250.00Hold → Buy
    Stifel
    Medtronic plc.
    $MDT
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    Oracle Corporation
    $ORCL
    6/18/2025$220.00 → $250.00Buy
    Guggenheim
    More analyst ratings

    $BFLY
    $MDT
    $ORCL
    $RXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      7/9/25 4:39:51 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      3/21/25 8:43:30 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Moorman Charles W bought $947,913 worth of shares (5,500 units at $172.35) (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      2/14/25 4:41:16 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $BFLY
    $MDT
    $ORCL
    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief HR Officer Walter Matthew R. was granted 4,350 units of Ordinary Shares, increasing direct ownership by 17% to 30,625 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      7/30/25 4:30:27 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EVP & Pres Neuroscience Wall Brett A. was granted 9,786 units of Ordinary Shares, increasing direct ownership by 24% to 51,282 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      7/30/25 4:29:12 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EVP Global Ops & Supply Chain Smith Gregory L was granted 9,786 units of Ordinary Shares, increasing direct ownership by 15% to 73,373 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      7/30/25 4:28:08 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BFLY
    $MDT
    $ORCL
    $RXRX
    SEC Filings

    See more
    • SEC Form 144 filed by Oracle Corporation

      144 - ORACLE CORP (0001341439) (Subject)

      7/16/25 12:25:21 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 25-NSE filed by Oracle Corporation

      25-NSE - ORACLE CORP (0001341439) (Subject)

      7/10/25 9:34:55 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Unregistered Sales of Equity Securities

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      7/8/25 8:19:11 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BFLY
    $MDT
    $ORCL
    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oracle Supports White House's Vision for Healthcare Data Interoperability

      Joins industry leaders in signing pledge to accelerate and simplify healthcare data sharing AUSTIN, Texas, July 30, 2025 /PRNewswire/ -- Oracle today pledged support for the Centers for Medicare and Medicaid Services' Digital Health Ecosystem and Interoperability Framework. During the Make Health Tech Great Again event at the White House, Oracle executives Mike Sicilia and Seema Verma committed to working with the federal government and industry leaders to deliver a more interoperable, secure, AI-enabled healthcare system that improves patient care, enhances provider experiences, and drives down the cost of care delivery.

      7/30/25 1:12:00 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • PNC Bank Announces Integration with Oracle Fusion Cloud ERP for Embedded Banking

      Connection Enables PNC PINACLE Connect® Clients to Seamlessly Access Treasury Services Within Market-leading Cloud ERP PITTSBURGH, July 29, 2025 /PRNewswire/ -- PNC Bank today announced the integration of its award-winning embedded banking platform, PINACLE Connect®, with Oracle Fusion Cloud Enterprise Resource Planning (ERP). PNC corporate and commercial banking clients now have seamless connectivity to key banking services directly within Oracle Cloud ERP, helping streamline financial operations and enhance overall efficiency. The new embedded banking experience, which uses

      7/29/25 8:01:00 AM ET
      $ORCL
      $PNC
      Computer Software: Prepackaged Software
      Technology
      Major Banks
      Finance
    • Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

      Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on August 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/pEH9b7wv2RxbrFDR7.Ab

      7/29/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BFLY
    $MDT
    $ORCL
    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Oracle with a new price target

      Scotiabank initiated coverage of Oracle with a rating of Sector Outperform and set a new price target of $300.00

      7/17/25 8:08:11 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Oracle upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Oracle from Neutral to Overweight and set a new price target of $270.00

      7/10/25 8:27:04 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Morgan Stanley resumed coverage on Recursion Pharmaceuticals with a new price target

      Morgan Stanley resumed coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $5.00

      7/3/25 7:50:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BFLY
    $MDT
    $ORCL
    $RXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

      GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

      7/8/25 8:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic Board appoints Dr. Joon Lee as a new director

      GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

      6/23/25 4:15:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    $BFLY
    $MDT
    $ORCL
    $RXRX
    Financials

    Live finance-specific insights

    See more
    • Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

      Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on August 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/pEH9b7wv2RxbrFDR7.Ab

      7/29/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Butterfly Network to Report Second Quarter 2025 Financial Results on August 1, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report second quarter 2025 financial results on August 1, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on August 1 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations websi

      7/18/25 8:05:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

      Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

      7/8/25 8:00:00 AM ET
      $RLYB
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BFLY
    $MDT
    $ORCL
    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 4:57:06 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 10:34:18 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/4/24 4:16:21 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care